In the U.S., cancer screening is limited to a few types, leaving many cancers undetected until advanced stages, contributing to approximately 70% of cancer deaths. Multi-cancer early detection (MCED) tests, which analyze blood for molecular signs of various cancers, are being developed and showing promise. Some tests, like Galleri, have led to early cancer diagnoses in patients, yet none have received formal regulatory approval or health insurance coverage, raising questions about reliability and follow-up procedures.
Many uncertainties still surround MCED tests, including determining which cancers they can detect reliably and how to follow up on positive tests.
Achieving broad access to the four cancer screening tests currently recommended in the United States has already proved to be challenging.
Collection
[
|
...
]